Skip to content
BIO FRONTIER
Home
Artificial intelligence
Biotechnology
Genetics
Medical Technology
VRTX
Home
VRTX
ABBV
AMGN
AMGN:CA
BAYRY
BAYZF
Biotechnology
BMY
GILD
IPSEF
IPSEY
JNJ
JNJ:CA
LLY
LLY:CA
NONOF
NOVO:CA
NVO
NVON:CA
NVS
NVS:CA
NVSEF
PFE
PFE:CA
REGN
RHHBF
RHHBY
RHHVF
Robert J. Lake
ROCH:CA
ROG:CA
SAN:CA
SNY
SNY:CA
SNYNF
Uncategorized
VRTX
ZLLY:CA
ZPFE:CA
Regeneron: Fairly Valued Now After A Stellar Upswing
Mar 11, 2026
Biotechnology
CRSP
Edmund Ingham
NTLA
Uncategorized
VRTX
Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here’s My Take
Mar 9, 2026
BEAM
Biotechnology
CRSP
NET
PFE
PFE:CA
Robert J. Lake
Uncategorized
VRTX
ZPFE:CA
Beam Therapeutics: Great Potential, But Patience Is Needed
Feb 27, 2026
Biotechnology
Uncategorized
VRTX
Vertex Q4 results miss on bottom line; 2026 revenue guidance in-line
Feb 12, 2026
Biotechnology
Uncategorized
VRTX
Vertex Pharma upgraded at RBC Capital Markets citing upside in 2026
Jan 22, 2026
Search for: